Scott
Steele
Ph.D.
Leadership Role
Acting
Director - Center for Biologics Evaluation and Research (CBER)
Scott Steele, Ph.D. is the Acting Director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration. Dr. Steele is a science, technology, and policy professional with extensive experience in multiple disciplines, including emerging science and technology, translational science, public health preparedness, and biodefense and medical countermeasures.
Dr. Steele moved into this executive role after serving as Senior Advisor for Translational Science in CBER’s Office of Center Director where he advanced horizon scanning and translational science programs, external partnerships, and policy initiatives in areas such as artificial intelligence and cellular and gene therapies. From 2020 - 2022, he served on an assignment in the FDA’s Center for Drug Evaluation and Research focused on science and policy priorities, including emerging technologies in drug development. From 2017 - 2020, he was a Special Government Employee on the FDA Science Board.
Before joining the FDA, Dr. Steele held multiple roles at the University of Rochester over nearly a 15-year period, most recently as the Director of Regulatory Science Programs at their Medical Center’s Clinical and Translational Science Institute and Associate Professor of Public Health Sciences.
Earlier in his career, he held positions in the White House’s Office of Science and Technology Policy, including as Executive Director of the President’s Council of Advisors on Science and Technology and Policy Analyst. There he provided advice and counsel on science and technology issues and led interagency groups across the government to enhance biotechnology, emerging technology development, U.S. competitiveness, and national security.
Dr. Steele holds both a doctorate and master’s in molecular biology from Princeton University, and a bachelor’s in biology from Union College.